Johnson & Johnson (NYSE:JNJ) is CWA Asset Management Group LLC’s 6th Largest Position

CWA Asset Management Group LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 182,287 shares of the company’s stock after selling 499 shares during the period. Johnson & Johnson comprises approximately 2.6% of CWA Asset Management Group LLC’s holdings, making the stock its 6th largest position. CWA Asset Management Group LLC’s holdings in Johnson & Johnson were worth $32,201,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD raised its stake in Johnson & Johnson by 18.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after buying an additional 3,912,430 shares during the last quarter. FMR LLC raised its stake in Johnson & Johnson by 20.8% during the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. Vanguard Group Inc. raised its stake in Johnson & Johnson by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. GQG Partners LLC raised its stake in Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock valued at $1,151,931,000 after buying an additional 2,547,378 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock valued at $1,083,329,000 after buying an additional 2,093,392 shares during the last quarter. 67.94% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Down 1.1 %

JNJ opened at $152.38 on Friday. The firm has a 50-day simple moving average of $161.97 and a two-hundred day simple moving average of $167.88. Johnson & Johnson has a 52 week low of $150.71 and a 52 week high of $186.69. The company has a market capitalization of $396.84 billion, a PE ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The business’s revenue was down 4.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.13 EPS. Analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is 67.06%.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. SVB Leerink cut their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Atlantic Securities boosted their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research report on Wednesday, January 25th. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating for the company. Finally, Citigroup boosted their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $174.73.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.